Oct. 5, 2015—NeoGenomics Laboratories has introduced the the NeoSite Cervical FISH Panel to aid diagnosis, classification, and monitoring progression and regression of cervical lesions including ASCUS, LSIL, HSIL, and CIN. Global and tech-only testing is now available.
The NeoSite Cervical FISH Panel, performed on ThinPrep® cytology samples, serves as an adjunct to cytology and HPV nucleic acid analysis. The panel determines copy numbers of five genomic loci that show nonrandom gains in precancerous and cancerous cervical lesions. These gains have been associated with progression of cervical cancer. Circumstances in which FISH testing may be considered include: ambiguous cytology on Pap smear (e.g. ASCUS, LSIL, HSIL); discordant cytology and HPV status; to differentiate high-risk vs. low-risk LSIL; decision-making for colposcopy versus monitoring and repeat Pap; monitoring precancerous lesions; and any clinical scenario calling for an additional prognostic indicator.
This is the only five-probe assay commercially available to evaluate chromosomal imbalances in cervical cancer, NeoGenomics said in a statement. The company said that in validation studies, the test demonstrated genomic instability in 98 percent of HSIL/HPV-positive lesions. Testing should be coordinated with HPV genetic analysis and cytology.